Proactive screening for symptoms: A simple method to improve early detection of unrecognized cardiovascular disease in primary care. Results from the Lifelines Cohort Study.

Atrial fibrillation Cardiovascular diseases Cohort studies Coronary artery disease Diagnostic screening programs Early diagnosis Heart failure Primary health care Signs and symptoms

Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
09 2020
Historique:
received: 28 01 2020
revised: 20 04 2020
accepted: 24 05 2020
pubmed: 31 5 2020
medline: 25 6 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

Cardiovascular disease (CVD) often goes unrecognized, despite symptoms frequently being present. Proactive screening for symptoms might improve early recognition and prevent disease progression or acute cardiovascular events. We studied the diagnostic value of symptoms for the detection of unrecognized atrial fibrillation (AF), heart failure (HF), and coronary artery disease (CAD) and developed a corresponding screening questionnaire. We included 100,311 participants (mean age 52 ± 9 years, 58% women) from the population-based Lifelines Cohort Study. For each outcome (unrecognized AF/HF/CAD), we built a multivariable model containing demographics and symptoms. These models were combined into one 'three-disease' diagnostic model and questionnaire for all three outcomes. Results were validated in Lifelines participants with chronic obstructive pulmonary disease (COPD) and diabetes mellitus (DM). Unrecognized CVD was identified in 1325 participants (1.3%): AF in 131 (0.1%), HF in 599 (0.6%), and CAD in 687 (0.7%). Added to age, sex, and body mass index, palpitations were independent predictors for unrecognized AF; palpitations, chest pain, dyspnea, exercise intolerance, health-related stress, and self-expected health worsening for unrecognized HF; smoking, chest pain, exercise intolerance, and claudication for unrecognized CAD. Area under the curve for the combined diagnostic model was 0.752 (95% CI 0.737-0.766) in the total population and 0.757 (95% CI 0.734-0.781) in participants with COPD and DM. At the chosen threshold, the questionnaire had low specificity, but high sensitivity. In conclusion, a short questionnaire about demographics and symptoms can improve early detection of CVD and help pre-select people who should or should not undergo further screening for CVD.

Identifiants

pubmed: 32473262
pii: S0091-7435(20)30167-5
doi: 10.1016/j.ypmed.2020.106143
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106143

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Victor W Zwartkruis (VW)

University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands.

Amy Groenewegen (A)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Frans H Rutten (FH)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Monika Hollander (M)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Arno W Hoes (AW)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

M Yldau van der Ende (MY)

University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands.

Pim van der Harst (P)

University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands; University Medical Center Utrecht, Utrecht University, Department of Cardiology, Utrecht, the Netherlands.

Maarten Jan Cramer (MJ)

University Medical Center Utrecht, Utrecht University, Department of Cardiology, Utrecht, the Netherlands.

Yvonne T van der Schouw (YT)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Hendrik Koffijberg (H)

University of Twente, Department of Health Technology & Services Research, Enschede, the Netherlands.

Michiel Rienstra (M)

University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands.

Rudolf A de Boer (RA)

University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, the Netherlands. Electronic address: r.a.de.boer@umcg.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH